TipRanks on MSN

Outlook Therapeutics Resubmits Biologics License Application

Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On November 3, 2025, Outlook Therapeutics announced the resubmission of its ...
Ophthalmology Times

Viridian Therapeutics submits Biologics License Application to FDA for veligrotug

Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...
The Joplin Globe

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...